No Data
No Data
泰凌醫藥:2023 年報
Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
Innovative drugs continue to warm up! Joint policies in many places catalyze the strengthening of the pharmaceutical sector in Hong Kong stocks
Recently, support policies for the innovative pharmaceutical industry have been issued in many places, bringing a new market catalyst to the currently relatively deserted pharmaceutical stocks. The Hong Kong stock pharmaceutical sector is also active today.
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
Tailing Pharmaceutical (01011) announced annual results. Shareholders' losses of 144 million yuan increased by 116.23% year-on-year
According to the Zhitong Finance App, Tailing Pharmaceutical (01011) announced the audited annual results for the year ended December 31, 2023. The group achieved continuous business revenue of 7.366 million yuan (RMB, same below) during the period, with no revenue in the same period of the previous year; shareholders should have accounted for a loss of 144 million yuan, an increase of 116.23% over the previous year; and a basic loss of 7.26 points per share. The announcement stated that the increase in revenue was due to a change in the business model in 2023.
No Data